Antiplatelet Therapy and the Post-ACS Patient
With 1.7 million hospital discharges per year, acute coronary syndrome (ACS) constitutes a significant burden of health. Learn the classes of anti-platelet therapies, review clinical trial data, learn about guideline-based use, and hear case presentations.
Upon completion of this continuing education course, participants will be able to:
- Identify the guidelines for dual antiplatelet therapy in the post-ACS patient.
- Identify the indications in which the risk of atherosclerotic cardiovascular disease outweighs the risk of bleeding, justifying the addition of a PAR-1 antagonist to standard dual oral antiplatelet therapy.
- List three classes of antiplatelet agents.
- David Anderson MS, MD, FACC, FSCAI